{"id":12159,"date":"2023-11-01T23:33:00","date_gmt":"2023-11-01T15:33:00","guid":{"rendered":"https:\/\/flcube.com\/?p=12159"},"modified":"2024-11-11T23:42:44","modified_gmt":"2024-11-11T15:42:44","slug":"immuxell-biotech-secures-over-rmb-100-million-in-series-a-funding-for-cell-therapy-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12159","title":{"rendered":"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development"},"content":{"rendered":"\n<p>ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in advancing the regulatory clinical studies for ImmuXell&#8217;s innovative KRAS G12V mutation-targeted TCR-T cell therapy, as well as supporting pipeline product development and fostering international cooperation.<\/p>\n\n\n\n<p><strong>Investor Support and Strategic Goals<\/strong><br>The Series A financing round reflects the confidence of leading investors in ImmuXell&#8217;s potential to revolutionize cell therapy. The proceeds will be directed towards bolstering the company&#8217;s ongoing clinical studies, particularly for its KRAS-targeted TCR-T cell therapy, which has already concluded an investigator-initiated trial (ITT) in advanced pancreatic ductal adenocarcinoma. This investment will also support the development of additional pipeline candidates, including a TCR-NK-targeted product and a TCR fusion protein candidate.<\/p>\n\n\n\n<p><strong>Company Background and Pipeline<\/strong><br>Founded in 2021, ImmuXell Bio has quickly established itself as a leader in the field of cell therapy, boasting a robust in-house product pipeline. The company&#8217;s lead candidate, the KRAS-targeted TCR-T cell therapy, represents a significant advancement in the treatment of cancers driven by the KRAS G12V mutation. ImmuXell&#8217;s commitment to innovation and its strategic approach to product development position it at the forefront of the biotech industry.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,77,20,2023],"class_list":["post-12159","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-cell-therapy","tag-finance","tag-immuxell-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in advancing the regulatory clinical studies for ImmuXell&#039;s innovative KRAS G12V mutation-targeted TCR-T cell therapy, as well as supporting pipeline product development and fostering international cooperation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12159\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12159\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-01T15:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-11T15:42:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12159#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12159\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development\",\"datePublished\":\"2023-11-01T15:33:00+00:00\",\"dateModified\":\"2024-11-11T15:42:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12159\"},\"wordCount\":245,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Cell-therapy\",\"Finance\",\"ImmuXell Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12159#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12159\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12159\",\"name\":\"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-01T15:33:00+00:00\",\"dateModified\":\"2024-11-11T15:42:44+00:00\",\"description\":\"ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in advancing the regulatory clinical studies for ImmuXell's innovative KRAS G12V mutation-targeted TCR-T cell therapy, as well as supporting pipeline product development and fostering international cooperation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12159#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12159\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12159#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development - Insight, China&#039;s Pharmaceutical Industry","description":"ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in advancing the regulatory clinical studies for ImmuXell's innovative KRAS G12V mutation-targeted TCR-T cell therapy, as well as supporting pipeline product development and fostering international cooperation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12159","og_locale":"en_US","og_type":"article","og_title":"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12159","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-01T15:33:00+00:00","article_modified_time":"2024-11-11T15:42:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12159#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12159"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development","datePublished":"2023-11-01T15:33:00+00:00","dateModified":"2024-11-11T15:42:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12159"},"wordCount":245,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Cell-therapy","Finance","ImmuXell Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12159#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12159","url":"https:\/\/flcube.com\/?p=12159","name":"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-01T15:33:00+00:00","dateModified":"2024-11-11T15:42:44+00:00","description":"ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in advancing the regulatory clinical studies for ImmuXell's innovative KRAS G12V mutation-targeted TCR-T cell therapy, as well as supporting pipeline product development and fostering international cooperation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12159#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12159"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12159#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12159"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12159\/revisions"}],"predecessor-version":[{"id":12161,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12159\/revisions\/12161"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}